This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Development Drugs Pharma Companies 
Pharmaceutical Technology
OCTOBER 28, 2022
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Remote-controlled robotic labs.
311 
Pharmaceutical Technology
OCTOBER 26, 2023
Experts discuss how pharma companies need to consider patient centricity earlier in their development plans.
130
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
AUGUST 26, 2022
The pharma company terminated a collaboration that could’ve netted the biotech about $350 million. It’s the latest in a string of recent setbacks for microbiome drug developers.
242 
Pharmaceutical Technology
JULY 17, 2024
As US China trade relations are set to be impacted by the BIOSECURE Act, pharma companies exploring CDMOs outside China may need to contend with increased drug development and manufacturing costs.
147 
Camargo
NOVEMBER 11, 2020
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.
242 
Bio Pharma Dive
JUNE 16, 2022
The German pharma company has secured an option to acquire Trutino Biosciences, two years after inking a research collaboration with the San Diego drug developer.
219 
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 11, 2025
Indian pharmaceutical industry plays a crucial role in the global drug supply chain, particularly in the US. Yet India needs to develop strategies to mitigate the impact of USAID funding freeze for Indian pharma companies.
147 
Pharmaceutical Technology
MARCH 6, 2023
Incannex Healthcare has collaborated with New Jersey-based pharma company Catalent for the development and manufacturing of a cGMP-grade psilocybin drug product for clinical trials and potential commercial use. Catalent will develop the formulation and produce the required data for regulatory filings.
264 
Pharmaceutical Technology
JUNE 15, 2023
AI for drug development is rapidly streamlining R&D processes, speeding up time to market and providing a better experience for patients and providers. Learn more about the role of AI in drug development and how healthcare researchers are using it to shake up the field.
130 
Pharmaceutical Technology
AUGUST 21, 2024
Pharma companies seeking to commercialise in mRNA can gain a competitive edge by partnering with expert suppliers
130 
World of DTC Marketing
FEBRUARY 21, 2022
Experts across the board are predicting demand for antiviral drugs will rapidly outpace supply. Pfizer and Merck have chosen to designate a select few generic manufacturers to produce cheaper versions of their drugs through the Medicines Patent Pool (MPP). Reportedly, the cost of production for molnupiravir stands at about $17.74.
218 
Pharmaceutical Technology
JUNE 15, 2023
The need for new medical treatments and drugs has never been greater. But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S.
130 
Pharmaceutical Technology
NOVEMBER 30, 2023
MSD is one of many pharma companies migrating IT applications to the cloud to transform value chains and harness new technologies.
130 
World of DTC Marketing
SEPTEMBER 7, 2022
In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies. They relied so much on a new drug that they tried to market a product with bad science behind it.
210 
pharmaphorum
SEPTEMBER 22, 2021
When the pandemic emerged, there was an urgent need for quick decisions and swift adaptability while continuing to ensure the safety of employees and limited disruption of the manufacturing and supply chain for much needed and potentially lifesaving drugs for patients. About the author.
111 
Pharmaceutical Technology
APRIL 17, 2023
Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. Olaratumab will be denoted as TLX300 in Telix’s development pipeline. But, following negative Phase III efficacy results, Lilly withdrew the drug from the market.
130 
Camargo
MARCH 9, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA revealed that pharma companies are not forthcoming when they publicly disclose the reasons behind a refuse-to-file (RTF) letter from the Agency.
146 
World of DTC Marketing
JANUARY 10, 2022
Pharma companies are flush with cash and looking to make deals, but there are still a lot of small biotech companies that don’t have enough money to launch their products entirely. A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3
213 
pharmaphorum
DECEMBER 19, 2023
Big pharma companies like Pfizer are making significant investments in antibody-drug conjugates, a promising class of therapies. This article explores the growing interest and recent developments, including FDA approvals and the potential impact on the pharmaceutical industry.
115 
Outsourcing Pharma
APRIL 19, 2024
revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing. Earlier this week, Charles River Laboratories International, Inc.
World of DTC Marketing
DECEMBER 9, 2021
LEAD IN: Pharma budgets are being scrutinized like never before, and DTC/HCP marketers must justify every dollar spent. 3hree: Developing an HCP portal on your website – Too little is a bad reflection on your brand; too much is a waste of money. ” The post Do you have enough money to launch your drug?
204 
Pharmaceutical Technology
NOVEMBER 3, 2023
Kronos Bio joins other pharma companies in workforce reductions, cutting 19% of its employees to support clinical development.
130 
World of DTC Marketing
JANUARY 26, 2022
As HCPs get more digitally savvy, pharma marketers should understand that engaging physicians through channels and time of their preference with content relevant to the individual customer. FutureReadyHealthcare listed the following key findings: 77% of HCPs use digital channels primarily for personal learning and development.
202 
pharmaphorum
MARCH 28, 2022
Noga Yerushalmi, investment director at M Ventures (the venture arm of Merck), tells us how AION Labs was formed and aspires to help ease the pharma industry’s shared challenges by offering its vast resources a new start-up. Then, a development stage or optimisation stage occurs. The partnership. ” The Application .
Pharmaceutical Technology
SEPTEMBER 23, 2022
For pharma and biotech companies, there are many advantages to partnering with a Contract Development and Manufacturing Organisations (CDMO): they can access more specialized knowledge, state-of-the-art equipment, and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market.
147 
Pharmaceutical Technology
JULY 21, 2022
AI also speeds up the drug development process, which could translate into cheaper drugs for patients. For pharma and medical device companies, 3D printing can reduce costs, waste, and the environmental burden. Orthopaedic companies have been using 3D printing for their implants for years. 3D printing.
245 
STAT News
JANUARY 6, 2023
Continuous manufacturing produces a drug product from start to finish through a nonstop, integrated assembly. In contrast, most of the pharmaceutical industry currently uses batch manufacturing, which involves producing a finished drug product through multiple distinct steps in series. I’m talking about continuous manufacturing.
111 
pharmaphorum
JUNE 14, 2022
China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline. Similar signs of growth can be seen in the amount of drugs, biologics and medical devices the country exports to the US. Only last month , the US company Merck agreed to pay a potential $1.4
World of DTC Marketing
SEPTEMBER 23, 2021
The suggestion by Pfizer’s CEO that drug pricing negotiations with the government would slow innovation is PR doubletalk. Here is his rationale: “ When we asked the Pfizer colleagues to develop a Covid-19 vaccine in l ess than a year, you did. To me, this says that the approval of the drug WAS about money, not patients.
214 
Outsourcing Pharma
MAY 23, 2024
A new report from Access to Medicine Foundation gives the advice to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance.
pharmaphorum
JULY 8, 2022
The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and development efforts, and its spend in this area has created a multibillion-dollar market for AI technologies. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.
131 
pharmaphorum
MAY 4, 2022
Testing drug compounds on a chip designed to mimic human organs sounds closer to science fiction than reality, yet the technology already exists and is already being put to use. The limits of animal models in drug discovery are well known. Quris has taken its technology and used it to develop its own drug candidate pipeline.
143 
World of DTC Marketing
JULY 15, 2021
SUMMARY: The Committee on Oversight and Reform and the Committee on Energy and Commerce is investigating the approval process for Biogen’s new Alzheimer’s drug. Janet Woodcock acknowledged on Wednesday her agency may have misstepped in the handling of its polarizing approval of a new Alzheimer’s drug.
202 
XTalks
DECEMBER 4, 2024
Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00
111 
World of DTC Marketing
APRIL 21, 2021
.” J&J has had problems in the past, but they’re trying to be an ethical and responsible pharma company. And we thought developing these vaccines was all about helping people during the pandemic.
273 
World of DTC Marketing
JANUARY 24, 2022
Venture capitalists have poured $42 billion into drug development over the past three years. Most small biotech companies rely on venture capitalist funding to develop new drugs but is that a good way to go? To them, a big payday is a small biotech firm being acquired by a big ten pharma company.
225 
Pharmaceutical Technology
AUGUST 1, 2022
Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.
234 
World of DTC Marketing
JANUARY 4, 2022
However, several gaps in our current understanding of this problem limit the development of highly effective solutions. Some cancer patients may face out-of-pocket costs of nearly $12,000 a year for one drug. Newly approved cancer drugs cost an average of $10,000 per month, with some as high as $30,000 per month. population.
273 
World of DTC Marketing
DECEMBER 8, 2021
LEAD-IN- Recent data confirms that health care professionals are using the Internet more and spending less time with drug company reps. According to metrics that I have reviewed for several brands, the most critical data for new drugs is the product label for HCPs. ” There is no one answer to that question. No, not at all.
213 
pharmaphorum
FEBRUARY 16, 2021
Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease. . It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.”.
119 
World of DTC Marketing
APRIL 5, 2022
Pharma companies have been investing deeply into digital advertising but vastly under measuring customer engagement and other metrics. Pharma marketers spend countless hours developing PowerPoints and getting approval for tactics, but they need specific listening metrics to pivot quickly if their plans aren’t effective.
196 
Delveinsight
JULY 21, 2021
However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease.
XTalks
OCTOBER 4, 2023
How is the shift toward value-based healthcare affecting drug pricing and reimbursement? There is a world where the way we have done things up until now from a pricing, health economics and access perspective is well-suited to meet the needs of drug reimbursement stakeholders, and where we would probably keep doing it.
105 
Pharmaceutical Technology
SEPTEMBER 2, 2022
The rate of drug approvals could be on the rise. In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. There are many reasons why a company might prefer to keep commercialisation activities inhouse.
130
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content